Benign Prostatic Hyperplasia Treatment Market Analysis, Trends & Forecast 2024

Benign Prostatic Hyperplasia Treatment Market

·         The global benign prostatic hyperplasia treatment market size reached USD 11.9 Billion in 2023.

·         The benign prostatic hyperplasia treatment market size is expected to reach USD 18.1 Billion by 2032, exhibiting a growth rate (CAGR) of 4.6% during 2024-2032.

·         Based on the region, the market is segregated into North America (the United States and Canada), Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and Middle East and Africa.

·         On the basis of treatment type, the market is segmented into drug class, minimally invasive surgeries, laser therapy, and others.

·         The rising prevalence of obesity and metabolic syndrome, as these conditions are linked to an increased risk of developing benign prostatic hyperplasia (BPH) symptoms, is impelling the market share.

·         Additionally, the expansion of telemedicine and digital health solutions is facilitating easier access to healthcare consultations and follow-ups for patients experiencing BPH symptoms, encouraging more individuals to seek diagnosis and treatment.

Request to Get the Sample Report:

https://www.imarcgroup.com/benign-prostatic-hyperplasia-treatment-market/requestsample

Industry Trends and Drivers:

·         The rising prevalence of BPH among the aging male population:

The rising prevalence of BPH among the aging male population is a significant driver of the market. BPH is a common condition that affects men, particularly those over the age of 50, and its incidence increases with age. As global demographics shift towards an older population, the number of individuals affected by BPH is projected to rise substantially. This trend is particularly pronounced in developed countries, where life expectancy is higher. The growing aging population not only leads to a higher prevalence of BPH but also increases the demand for effective treatment options.

Men experiencing symptoms such as frequent urination, nocturia, and urinary retention seek medical advice that can alleviate these symptoms and improve their quality of life, bolstering the market demand.

·         Advancements in treatment options and technologies:

Advancements in treatment options and technologies are propelling the BPH Treatment market. Historically, treatment options for BPH included medications and surgical procedures, but recent innovations have expanded the range of available therapies. New medications, such as alpha-blockers and 5-alpha-reductase inhibitors, have been developed to provide better symptom relief with fewer side effects.

Additionally, minimally invasive surgical techniques, including transurethral resection of the prostate (TURP) and laser therapies, offer effective alternatives to traditional surgery, leading to shorter recovery times and reduced hospital stays. The introduction of novel therapies, such as prostate artery embolization and aquablation, has also enhanced treatment options, providing patients and healthcare providers with more choices thus contributing to the market expansion.

·         Increasing awareness and diagnosis of the condition:

Awareness campaigns and educational initiatives by healthcare organizations aim to inform men about the symptoms and risks associated with BPH. Improved access to healthcare services and diagnostic tools, such as digital rectal exams and prostate-specific antigen (PSA) tests, facilitate early detection and timely treatment. As men become more informed about their health and the availability of treatment options, they are more likely to seek medical intervention for their symptoms. This heightened awareness contributes to a larger patient pool and increased demand for BPH therapies, thereby propelling the market forward.

Furthermore, the growing acceptance of discussing prostate health issues reduces stigma, and encouraging men to address their symptoms and pursue appropriate treatments is aiding the market growth.

Benign Prostatic Hyperplasia Treatment Market Report Segmentation:

Breakup By Treatment Type:

·         Drug Class

o    Alpha-Blockers

o    5-Alpha-reductase Inhibitors (5-ARIs)

o    Phosphodiesterase-5 Enzyme Inhibitors

o    Others

·         Minimally Invasive Surgeries

o    Transurethral Resection of the Prostate (TURP)

o    Transurethral Incision of the Prostate (TUIP)

o    Transurethral Microwave Thermotherapy (TUMT)

o    Robotic Surgeries

o    Prostatic Urethral Lifts

o    Others

·         Laser Therapy

·         Others

Based on treatment type, the market is segmented into drug class, minimally invasive surgeries, laser therapy, and others.

Breakup By Region:

·         North America

·         Asia Pacific

·         Europe

·         Latin America

·         Middle East and Africa

Based on the market forecast, the region is segregated into North America (the United States and Canada), Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and Middle East and Africa.

Top Benign Prostatic Hyperplasia Treatment Market Leaders:

The benign prostatic hyperplasia treatment market research report outlines a detailed analysis of the competitive landscape, offering in-depth profiles of major companies.

Some of the key players in the market are:

·         Abbott Laboratories

·         Allergan Plc (AbbVie Inc.)

·         Asahi Kasei Corporation

·         Astellas Pharma Inc.

·         Boehringer Ingelheim GmbH (C.H. Boehringer Sohn AG & Ko. KG)

·         Boston Scientific Corporation

·         GlaxoSmithKline Plc

·         Pfizer Inc.

·         Sanofi S.A. 

      Teva Pharmaceutical Industries Ltd.

      Ask Analyst for Customized Report:

https://www.imarcgroup.com/request?type=report&id=2898&flag=C

Key Highlights of the Report:

·         Market Performance (2018-2023)

·         Market Outlook (2024-2032)

·         Market Trends

·         Market Drivers and Success Factors

·         Impact of COVID-19

·         Value Chain Analysis

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group

134 N 4th St

Brooklyn, NY 11249, USA

Website: imarcgroup.com

Email: sales@imarcgroup.com

Americas: +1-631-791-1145 | Europe & Africa: +44-753-713-2163 | Asia: +91-120-433-0800